Fig. 1From: Preferable effects of pemafibrate on liver function and fibrosis in subjects with type 2 diabetes complicated with liver damageChanges in alanine transaminase before and at the end of the study periodBars are the median (25–75%). * p < 0.05, *** p < 0.001 between 0 and 52 weeks (Wilcoxon’s signed-rank test for within-group comparisons, and Mann-Whitney U-test for changes between groups). Light and dark green bars represent 0 and 52 weeks in the pemafibrate group, and white and gray bars represent 0 and 52 weeks in the control group. ALT, alanine aminotransaminase; ULN, upper limit of normal, Pema, pemafibrate, Ctrl, control, NS, not significantBack to article page